31 January 2019

Researchers of the Orthopaedic Research Laboratory of the Radboudumc, together with the LUMC, received a grant of €180k from the Innovatiefonds Zorgverzekeraars for clinical implementation of patient-specific computer models for fracture risk prediction in patients with bone metastases.

Patients with cancer can suffer from bone metastases in the femur. These bone metastases are usually very painful and increase the risk of a fracture. Treatment of bone metastases is based on the fracture risk: patients with a low fracture risk will be treated with radiotherapy for pain management, whereas patients with a high fracture risk are considered for preventive surgery. According to current clinical guidelines, fracture risk is assessed by measuring the size of the metastases on X-rays or CT scans. However, it appears that using this method, there are patients who receive unnecessary preventive surgery, as well as patients who fracture their femur although they were assessed as low risk.
 
Computer simulation
The research team of the Radboudumc, consisting of Nico Verdonschot, Esther Tanck and PhD candidate Florieke Eggermont, and Yvette van der Linden of the LUMC, developed a patient-specific computer simulation that can predict fracture risk in patients with bone metastases. This computer simulation calculates bone strength based on a CT scan, and appears to be better at estimating fracture risk in comparison to the clinical guidelines. Therefore, they received a grant of €180k from the Innovatiefonds Zorgverzekeraars to initiate clinical implementation of the computer model. The idea is that clinicians can order a computer simulation at the Orthopaedic Research Lab if they are unsure about the patient’s fracture risk. They will then receive a patient-specific fracture risk prediction based on the calculations, which can be used in the consultation with the patient to determine the best treatment option.
 
Florieke Eggermont, Esther Tanck and Nico Verdonschot are members of theme Reconstructive and regenerative medicine.

Related news items


650,000 Euro funding for research into the phasing out of medication for leukaemia patients

30 July 2020

With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.

read more

Increased role of patients after bowel cancer treatment

30 July 2020

Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.

read more

ERC Proof of Concept grant received by Ronald van Rij

30 July 2020

Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.

read more

Hypatia fellowship Call is open

30 July 2020

The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.  

read more

Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation. 

29 July 2020

These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.

read more

Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process

28 July 2020

''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.

read more